Disposable intravenous infusion sets as a temporary intravascular shunt for major limb replantation: a retrospective study - Top-Institutions - MDSpire

Disposable intravenous infusion sets as a temporary intravascular shunt for major limb replantation: a retrospective study

  • By

  • Shanqing Yin

  • Chenxi Zhang

  • YaoPeng Huang

  • linHai Liu

  • JiaDong Pan

  • Xin Wang

  • December 30, 2024

  • 0 min

Share

Top Institutions in Surgery

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Microsurgery
    • Trauma Surgery
    • Vascular Surgery
    • Reconstructive Surgery

  • #2

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, MA

    Key Differentiators

    • Microsurgery
    • Trauma Surgery
    • Vascular Surgery

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Reconstructive Surgery
    • Microsurgery
    • Trauma Surgery

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Microsurgery
    • Trauma Surgery
    • Vascular Surgery

  • #5

    Hospital for Special Surgery (HSS)
    Hospital for Special Surgery (HSS)

    New York, NY

    Key Differentiators

    • Orthopedic Surgery
    • Microsurgery
    • Reconstructive Surgery

Original Source(s)

Disposable intravenous infusion sets as a temporary intravascular shunt for major limb replantation: a retrospective study

  • by Shanqing Yin, Chenxi Zhang, YaoPeng Huang, linHai Liu, JiaDong Pan, Xin Wang

  • December 30, 2024

Related Content

Surgeon Volume and Clinical Outcomes After Robotic Elective and Emergency General Surgery

Can Casting Match Surgery for Pediatric Fractures?

Randomized trial finds small early functional differences that resolve over time, with lower costs and fewer early complications.

FDA Expands Marstacimab Indication in Hemophilia A and B

Phase 3 BASIS and BASIS KIDS data supported the expanded indication across pediatric and inhibitor-pretreated populations.